**AUB KQ1 Evidence Table (Reference ID #76)**

| **Study Description** | **Intervention(s)/ Comparator(s)** | **Patient Population** | **Baseline Measure(s)** | **Outcome Measure(s)** | **Overall Quality****Risk of Bias** |
| --- | --- | --- | --- | --- | --- |
| **Author:**Karakus et al., 2009**Country:**Turkey**Enrollment** **period:**August 2004 to April 2005**Intervention** **setting:** Outpatient clinic**Funding:**NR**Author industry relationship disclosures:**NR**Study Design:** RCT**Blinding:** None  | **Intervention:**Vaginal micronized progesterone (8% gel) 90 mg, every other evening from menstrual cycle day 17 to 27**Comparator:**Dydrogesterone 10 mg orally twice daily for 10 days starting on cycle day 15 **Groups:****G1:** Vaginal progesterone**G2:** Oral progesterone**Followup:**3 cycles | **Inclusion criteria:** * Aged 35 to 45 years
* No menopausal symptoms
* Did not take hormone therapy
* Diagnosed with dysfunctional uterine bleeding
* No contraindication for progesterone or progestins
* Endometrial thickness >5 mm by transvaginal ultrasound

**Exclusion criteria:** Taking anticoagulants or antiprostaglandinsPrefer hormonal contraceptive methodsKnown intolerance to progesterone or progestins**N at enrollment:** **G1:** 34**G2:** 35**N at followup:** **G1:** 27**G2:** 27**Age, mean years ± SD:****G1:** 39.1 ± 3.6**G2:** 39.6 ± 3.0**BMI, mean kg/m2 ± SD:****G1:** 29.2 ± 5.4**G2:** 30.3 ± 3.7**G1 vs. G2:** p=0.371**Gravidity, mean ± SD:****G1:** 4.4 ± 2.1**G2:** 4.8 ± 2.3**G1 vs. G2:** p=0.584**Parity, mean ± SD:****G1:** 3.0 ± 1.4**G2:** 3.6 ± 2.2**G1 vs. G2:** p=0.209**Race/ethnicity:**NR | Secretory endometrium in endometrial sample, n (%):**G1:** 8 (29.6)**G2:** 6 (22.2)**G1 vs. G2:** p=0.412 | **Bleeding:**Irregular bleeding pattern,a n (%):First cycle:**G1:** 2 (7.4)**G2:** 5 (18.5)**G1 vs. G2:** p=0.42Second cycle:**G1:** 3 (11.1)**G2:** 3 (11.1)**G1 vs. G2:** p=1.0Third cycle:**G1:** 2 (7.4)**G2:** 4 (14.8)**G1 vs. G2:** p=0.67Secretory endometrium in endometrial sample, n (%): **G1:** 24 (88.9)**G2:** 22 (81.5)**G1 vs. G2:** p=0.732**Quality of life:**NR**Pain:**NR**Sexual function:**NR**Patient satisfaction:**Self-reported patient satisfaction with treatment, n (%):**G1:** 23 (85)**G2:** 21 (78) **G1 vs. G2:** p=0.491**Fertility:**NR**Time to conception:**NR**Additional interventions:**See comment**b****Adverse events, n:**Groin pain:**G1:** 1**G2:** 05-kg weight gain:**G1:** 1**G2:** 0Ovarian cyst:**G2:** 1**G2:** 0 | **Overall quality:**Poor**Risk of bias:** Randomization: LowAllocation concealment:HighSelective reporting:UnclearBlinding patients/personnel:HighBlinding outcome assessment:UnclearIncomplete outcome reporting:HighOther:Unclear |

**Table Notes**: a Regular bleeding: cycle length less than 35 days and no intermenstrual bleeding; b Oral estrogen added for n=1 in G2 because of 45-day menstrual delay.